Gilead’s $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos

Summary: Gilead Sciences is spending over $2 billion to buy a company called Ouro Medicines. They really want Ouro's special new medicine, OM336. This medicine is a "T-cell engager" that helps the body's immune system fight autoimmune diseases, which are conditions where the body accidentally attacks its own healthy blood cells.

Gilead is also giving its partner company, Galapagos, a big new job. Galapagos had been struggling to find a purpose, but now they will pay for half of this new deal and do the hard work to test the medicine in labs. If the medicine is a success and gets sold, Galapagos will get a cut of the money.

For more details, see rssapp-fiercebiotech-com at fiercebiotech.com/biotech/gileads-22b-ouro-buyout-delivers-autoimmune-tce-new-purpose-galapagos (opens in new tab)